News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation
NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Tan JCO PRecis Oncol 2022 epigenetics germline
Beckman Coulter Life Sciences and Pillar Biosciences Sign Application Development Agreement for the Biomek NGeniuS System
INDIANAPOLIS – (October 31, 2022) – More companies around the world continue turning to Beckman Coulter Life Sciences, a global leader in laboratory automation and
Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference
NATICK, Mass. – August 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products
Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal™ Dx Colon Cancer Assay
– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass. – August 22, 2022
Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit
NATICK, Mass. – August 5, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products